Longs Vs. Shorts In Ligand Pharma: Roth Capital Analyst Squares Up Against Hedge Fund
July 29, 2015 at 15:18 PM EDT
In a report rolled out Wednesday, Roth Capital analysts Joseph Pantginis and Assaf Vestin reiterated a Buy rating and $135.00 price ...
